Shares of ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) surged over 20% in early trade after the European Patent Office granted a patent (number EP 2 836 221) for its Cholesterol Efflux Mediator VAR 200 in the treatment of diabetic nephropathy/diabetic kidney disease.

ZyVersa's VAR 200 is currently in phase 2a development, aiming to address renal cholesterol and lipid accumulation, which can contribute to kidney damage in patients with various glomerular diseases, including diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome.

$ZVSA is currently trading at $0.29, reflecting a significant increase of $0.05 (+21.69%).

In other news, the financial advisory firm Lake Street reiterated a Buy rating and maintained a price target of $32 for Castle Biosciences, Inc. (Nasdaq: CSTL).

Castle Biosciences, a prominent molecular diagnostics company, will be presenting new data on its gene expression profile (GEP) risk-stratification tests, specifically DecisionDx-SCC for cutaneous squamous cell carcinoma (SCC) and DecisionDx-Melanoma for cutaneous melanoma (CM), at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer.

$CSTL is trading at $19.12, up $5.84 (43.98%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)